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Background: Platelet response to activating agents is used to monitor the efficacy of anti-aggregation
therapies. The aim of our study has been to demonstrate the existence of relationships between early
events of ADP-induced platelet activation, measured by flow cytometry and platelet-rich plasma aggrega-
tion, quantified by optical aggregometry.
Methods: We evaluated peripheral blood of 12 donors. The following parameters were quantified by
cytometry after stimulation with adenosine diphosphate (ADP) (0.5, 1, 2, 5, 10, 20 lM): CD62P (P-selectin)
and PAC-1 expression, and cytosolic Ca21 mobilization. Aggregation was measured by optical aggregome-
try. We also studied 13 patients, undergoing coronary stenting, treated with aspirin (before procedure) or
with aspirin plus clopidogrel (after procedure). We evaluated CD62P and PAC-1 expression, aggregation,
and vasodilator-stimulated phopshoprotein phosphorylation (platelet reactivity index, PRI).
Results: Flow procedures were more sensitive than aggregometry, with a lowest interindividual variabili-
ty. Linear relationships existed in donors between CD62P expression and Ca21 mobilization (P < 0.0001),
and between aggregation and Ca21 mobilization (P < 0.0001). Linear relationships existed between
aggregation and CD62P expression, as percentage (P < 0.0001), or relative fluorescence intensity
(RFI) (P < 0.0001). Exponential equations related aggregation and PAC-1 expression, as percentage
(P < 0.0001), or RFI (P < 0.0001). Linear relationships between aggregation and CD62P expression
(as percentage) existed in the patients before (P 5 0.0022) and after procedure (P 5 0.0020). Expo-
nential relationships between aggregation and PAC-1 expression (as percentage) existed before (P 5
0.0012) and after procedure (P 5 0.0024). Linear correlations related aggregation response pre-
dicted on CD62P expression, and measured aggregation inhibition after clopidogrel (P 5 0.0013) as
well as predicted aggregation and PRI inhibition (P 5 0.0031).
Conclusions: Tight relationships between aggregation and cytometric quantification of platelet markers
in whole blood, in particular CD62P, allow to predict aggregation response to ADP from flow data in patients
treated with aspirin alone or with aspirin plus clopidogrel. q 2007 Clinical Cytometry Society
Key terms: platelet; ADP; optical aggregometry; flow cytometry; anti-aggregation therapies
How to cite this article: Sbrana S, Pina FD, Rizza A, Buffa M, De Filippis R, Gianetti J, Clerico A. Relationships
between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
Cytometry Part B 2008; 74B: 30–39.
Platelet aggregation represents the final step of a
complex activating sequence in which the contact
with a damaged endothelium and/or with soluble fac-
tors of the coagulation pathway triggers dramatic in-
tracellular changes such as cytoskeleton rearrange-
ment and shape change, release reaction of stored
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granules, and membrane glycoproteins modifications
(1–3).
Exogenous added adenosine diphosphate nucleotide
(ADP) and ADP released from platelet dense bodies fol-
lowing activation bind two types of platelet G-protein
coupled purinergic receptors (P2Y1 and P2Y12) (4,5). It
appears that P2Y1 has a role in the initiation of platelet
activation, while P2Y12 is essential for a sustained, full
aggregation response to ADP (6). A reciprocal cross-talk
between P2Y1 and P2Y12 has been also demonstrated at
the level of calcium signaling in human platelets (7).
The P2Y12 receptor stimulation by ADP is inhibited by
clopidogrel, a thienopyridine prodrug, which has to be
metabolized in the liver to acquire its anti-platelet aggre-
gation properties (8). The normal P2Y12 stimulation by
ADP determines the dephosphorylation of the vasodila-
tor-stimulated phosphoprotein (VASP), an intracellular
actin regulatory protein involved in platelet cytoskeletal
rearrangement, and GPIIb-IIIa conformational changes.
Conversely, inhibition of P2Y12 receptor by clopidogrel
induces phosphorylation of VASP (9). Flow cytometric
quantification of intraplatelet VASP phosphorylation is
now widely used to monitor the efficacy of clopidogrel
therapy in ischemic cardiovascular diseases (10,11).
The aim of our study has been to demonstrate in
healthy subjects the presence of relationships between
the early events of ADP-induced platelet activation meas-
ured by flow cytometry, such as Ca2þ mobilization, a-
granules release (CD62P expression), GPIIb-IIIa receptor
conformational changes (PAC-1 expression), and the
quantification of maximal platelet-rich plasma (PRP)
aggregation by optical aggregometry (type Born). More-
over, we investigated the role of platelet activation
markers (CD62P and PAC-1) in predicting the aggrega-
tion response to ADP in ischemic patients undergoing
elective coronary stenting, and treated with aspirin alone
(before procedure) or with a combination of aspirin plus
clopidogrel (after procedure).
MATERIALS AND METHODS
Donors, Patients, and Specimens
Whole blood was obtained from 12 healthy adult vol-
unteers (range 26–45 years, with a male/female ratio of
6/6) who had not taken medications or anti-platelet
drugs for the preceding 2 weeks. To reduce artefactual
platelet activation, blood samples were drawn from an
antecubital vein using a 19-gauge needle, and the first
2.5 ml were discarded. All samples for flow cytometric
and aggregometric evaluations were collected in Vacu-
tainer tubes (Becton Dickinson, San Jose, CA) containing
3.8% trisodium-citrate solution as anticoagulant.
We also studied 13 patients who had ischemic disease
and were undergoing elective coronary stenting. Pa-
tients’ mean age was 71 years (range 58–85 years, with
a male/female ratio of 8/5). Over the daily therapy with
aspirin (100 mg/day), all patients started treatment
with clopidogrel. In particular, they received a loading
dose of clopidogrel (300 mg) immediately after stenting,
followed by a regimen therapy of 75 mg/day. Patients’
blood was drawn under therapy with aspirin alone
(before procedure), and 48 h after stenting, under a
combination therapy of aspirin and clopidogrel (after
procedure).
The study protocol was approved by the local ethical
committee, and informed consent was obtained from
each subject before enrollment.
Data Acquisition and Analysis
Platelet count in PRP was carried out with the auto-
mated cell analyzer SF-3000 (SYSMEX, Kobe, Japan).
Flow cytometry was performed with a FACScan instru-
ment and CellQuest software (Becton Dickinson). Over-
time monitoring of instrumental performance was car-
ried out with CaliBRITE beads (Becton Dickinson). Flow
data analysis of platelet surface molecules and intracellu-
lar calcium mobilization was based on measurement of
positive events (percentage), or on their relative fluores-
cence intensity (RFI) quantification, using the statistic
function of overlaid and subtracted histograms (12). The
presented net values of data (percentages or RFI) con-
cerning CD62P and PAC-1 surface staining were calcu-
lated after subtracting the values measured in resting
samples from that obtained following ADP activation.
This calculation excludes that the level of platelet activa-
tion observed after addition of exogenous ADP depends
also by ADP released from erythrocytes.
No spontaneous Ca2þ mobilization or PRP aggregation
was observed in resting condition (addition of PBS
alone).
Aggregometry was performed with a dual channel op-
tical aggregation system (CHRONO-LOG series 490,
Havertown, PA), equipped with an infra red light beam
and the AGGRO/LINK software (CHRONO-LOG).
Sample Preparation for Flow Cytometric Analysis
Platelet activation markers
CD62P. Five microliter samples of 3.8% trisodium-ci-
trate anticoagulated blood were gently suspended in 30
ll of N2-hydroxy-ethyl-piperazine-N0-2-ethanesulfonic
acid (HEPES)-buffered phosphate saline (PBS) solution,
containing appropriate volumes of fluorescein isothiocya-
nate (FITC) CD41a (Becton Dickinson) and phycoery-
thrin (PE) conjugated CD62P (Pharmingen, San Diego,
CA) monoclonal antibodies, together with different final
concentrations of ADP (0.5, 1, 2, 5, 10, 20 lM) (code
number A-2754) (Sigma Chemical, St. Louis, MO). A rest-
ing sample was also performed to determine the sponta-
neous level of CD62P expression. All samples were incu-
bated for 8 min at room temperature (RT) in the dark.
For each activation point, a mouse isotype control was
carried out in parallel. At the end, the samples were
diluted and fixed with 500 ll of ice-cold 1.0% formalde-
hyde solution in PBS, and maintained on ice until ana-
lyzed.
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PAC-1. Whole blood samples were treated according
to the manufacturer’s instructions, as already described
(13). In brief, 5 ll of trisodium-citrate anticoagulated
blood were gently suspended in a mixture containing
appropriate volume of CD61 (PE; Immunotech, Beckman
Coulter, Fullerton, CA) and PAC-1 (FITC; Becton Dickin-
son) monoclonal antibodies, together with different final
concentrations of ADP (0.5, 1, 2, 5, 10, 20 lM) (Sigma
Chemical). A resting sample was also performed to
determine the spontaneous level of PAC-1 expression.
All samples were incubated for 8 min at RT in the dark.
For each activation point, a mouse isotype control was
carried out in parallel. Then, the samples were diluted
and fixed with 500 ll of ice-cold 1.0% formaldehyde so-
lution in PBS, and maintained on ice until flow analysis.
For both staining procedures, the acquisition process
was stopped after 20,000 platelets gated morphologically
by a dual-parameter plot of four-decade log scales of side
versus forward scatter, or on the basis of their CD41a
(FL1) and CD61 (FL2) bright fluorescence intensities
were collected for each sample (Fig. 1).
Kinetic measurement of intracellular platelet
Ca2þ mobilization. Blood samples were treated accord-
ing to the flow cytometric procedures already described
(14), with some modifications. In brief, 100 ll of triso-
dium-citrate anticoagulated whole blood, diluted 1:10 in
Krebs–Ringer bicarbonate buffer (K 4002) (Sigma Chemi-
cal) modified by addition of sodium bicarbonate
(NaHCO3) 1.26 g/l, bovine serum albumin 0.35%, and
HEPES 10 mM were loaded with the fluorescent calcium
indicator Fluo-4, AM (Molecular Probes, Eugene, OR) (5
lM final) by incubating for 30 min at 378C in the dark.
To assist the dispersion in aqueous media of the nonpo-
lar tracer Fluo-4 and reduce the leakage from platelets of
its de-esterified form, we supplemented the staining
buffer with the nonionic surfactant Pluronic1F-127 (Mo-
lecular Probes) (0.02% final) and with the anion-trans-
port inhibitor probenecid (2.5 mM final), as already
described (15–17). At the end, the loaded suspension
was gently resuspended and 25 ll of diluted blood were
incubated with 5 ll of CD41a (PE) (Pharmingen) mono-
clonal antibody, for 15 min at RT in the dark, to identify
platelet population. Then, stained samples were further
diluted with 1 ml of modified buffer, and aliquots of 500
ll, maintained at RT in the dark, were used to determine
kinetic variations of intracellular Ca2þ. After an initial ac-
quisition of 25 s of baseline at low speed, in which the
instruments aspirates 5 ll of suspension, we added to
FIG. 1. Representative example of
ADP-induced platelet activation (0.5
lM) in whole blood sample. The pla-
telets, previously clustered by a
dual-parameter dot plots of side ver-
sus forward scatter, both collected
in four-decade log scales, are subse-
quently identified on the basis of
their bright CD41a (FL1; A) and
CD61 (FL2; C) fluorescence inten-
sities. The overlaid histograms sub-
traction (test histogram–control his-
togram) (B, D) is used to quantify
the percentages of CD62P and PAC-
1 positive platelets (events in M2,
filled histograms) and their RFI
(linear scale) with respect to the cor-
responding isotype controls (dotted
histograms).
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each sample 5 ll of appropriate ADP working solutions,
to obtain final agonist concentrations of 0.5, 1, 2, 5, 10,
20 lM. The entire acquisition process was stopped after
about 8 min starting from ADP addition (Fig. 2).
Platelet VASP phosphorylation. Intracellular plate-
let VASP phosporylation level was measured in the
patients using the dedicated PLT VASP/P2Y12 kit (Bio-
cytex, Marseille, France). The staining procedure and the
calculation of the platelet reactivity index (PRI) were
performed according to the manufacturer’s protocol.
Plasma Samples and Aggregometry
PRP was prepared by slow centrifugation at 100g for
15 min, at RT. The remaining blood was recentrifuged at
2400g for 20 min, at RT, to obtain Platelet-Poor Plasma.
Appropriate ADP working solutions in PBS were pre-
pared to reach the scheduled final concentrations of
agonist (0.5, 1, 2, 5, 10, 20 lM). The aggregation pro-
cess was monitored over 8 min starting from agonist
addition (50 ll of working solution) to stirred PRP ali-
FIG. 2. Representative example of
ADP (20 lM)-induced intracellular
platelet Ca2þ mobilization in whole
blood sample. The Fluo-4 loaded
platelets, previously clustered by a
dual-parameter dot plots of side ver-
sus forward scatter, both collected
in four-decade log scales, are subse-
quently identified on the basis of
their bright CD41a (FL2; A and C)
fluorescence intensity. The dual-pa-
rameter dot-plots of FL1 versus time
show the changes over-time in Fluo-
4 fluorescence intensity after stimu-
lation (arrow) with ADP (20 lM
final) (D) or with an irrelevant stimu-
lus (PBS alone) (B). In the overlaid
histograms subtraction of test histo-
gram–control histogram (R1 þ R2
gated) (E), the percentage of ADP-
responding platelets and their RFI
(events in M1, filled histogram) are
compared with the PBS-stimulation
(dotted histogram), over 8 min.
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quots (450 ll) into glass tubes preheated to 378C.
Before each measurement, the aggregometer was cali-
brated at 100% of transmittance, according to the manu-
facturer’s instructions.
Statistical Analysis
Mean values of measurements and their standard
errors of the mean, as well as the relationships among
the different groups of data, were determined with the
StatView 5.0 software (SAS Institute, Cary, NC). The
choice of relationships between platelet functional pa-
rameters or between platelet functional parameter and
PRP aggregation was always based on the evaluation of
best statistical significance characterizing the fitting
curve. P < 0.05 was considered statistically significant.
RESULTS
The accuracy of flow cytometric procedures (coeffi-
cients of variation, C.V.) was determined on blood from
one healthy donor by 10 repeated measurements follow-
ing platelet activation with ADP 5 lM (Table 1).
Also optical aggregometry exhibited a good reproducibil-
ity at the same activatory conditions, with a C.V. of 6.7%.
As shown in Figure 3, flow cytometric procedures per-
formed on blood from healthy donors, in particular PAC-
1 expression, are more sensitive (higher percentage of
response) than optical aggregometry in evaluating plate-
let activation induced by low concentrations of ADP (0.5
and 1 lM). Moreover, flow procedures reach a plateau
of response more rapidly than aggregometry. Finally, op-
tical aggregometric response exhibits a larger interindi-
vidual variability, starting from ADP 1 lM, when com-
pared with flow cytometric protocols.
The relationship observed in healthy subjects between
CD62P surface expression (percentage of positivity) and
platelet Ca2þ mobilization (percentage of responding pla-
telets) (Fig. 4A), following activation with increasing
ADP concentrations, is described by the equation:
y ¼ 2:568x 47:423 ð1Þ
with R2 ¼ 0.9899 and P < 0.0001.
The linear regression existing between PRP maximal
aggregation and platelet Ca2þ mobilization (Fig. 4B) is
described by the equation:
Table 1
Coefficients of Variation (C.V.) of Flow Cytometric Procedures
CD62P PAC-1 Ca2þ
% Positive events 1.9% 0.3% 2.9%
RFI 2.4% 1.7% 2.4%
RFI, relative fluorescence intensity.
FIG. 3. Graph showing the differences observed between flow cytom-
etry and optical aggregometry in quantifying the percentages of
responding platelets following ADP-induced activation. The reported
percentages (net values) of CD62P and PAC-1 positive events are cal-
culated after subtracting the values measured in resting samples.
Moreover, no Ca2þ mobilization or PRP aggregation was observed using
an unrelated stimulus (PBS alone).
FIG. 4. Relationships between platelet Ca2þ mobilization and
CD62P expression (A) as well as between platelet Ca2þ mobilization
and PRP aggregation (B), after stimulation with different concentra-
tions of ADP (0.5, 1, 2, 5, 10, 20 lM). Each point represents the
mean values of 12 independent experiments. See the text for the cor-
responding equations and statistical significance.
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y ¼ 5:229x 134:372 ð2Þ
with R2 ¼ 0.9903 and P < 0.0001.
A linear regression characterizes also the relationship
between PRP maximal aggregation and CD62P surface
expression (percentage of positivity) as follows (Fig. 5A):
y ¼ 2:031x 37:556 ð3Þ
with R2 ¼ 0.9953 and P < 0.0001, while PRP maximal
aggregation and PAC-1 surface expression (percentage of
positivity) are related by the following exponential func-
tion (Fig. 5B):
y ¼ e0:315x  3:891  108 ð4Þ
with P < 0.0001.
Similarly, when comparing PRP maximal aggregation
and CD62P RFI (Fig. 6A), we obtain a linear regression:
y ¼ 1:196x 44:672 ð5Þ
with R2 ¼ 0.9893 and P < 0.0001, while an exponential
function relates PRP maximal aggregation and PAC-1 RFI
(Fig. 6B):
y ¼ e0:05x  2:0  103 ð6Þ
with P < 0.0001.
The relationships found in healthy donors between
the mean expressions of platelet activation markers
(CD62P and PAC-1) and the mean values of PRP maximal
aggregation, in response to different ADP concentra-
tions, seem to be maintained also in patients treated
with aspirin alone or a combination of aspirin plus clopi-
dogrel.
In fact, linear regressions relate PRP maximal aggrega-
tion and CD62P surface expression (percentage of posi-
FIG. 5. Relationships between CD62P expression and PRP aggrega-
tion (A) as well as between PAC-1 expression and PRP aggregation (B),
after stimulation with different concentrations of ADP (0.5, 1, 2, 5,
10, 20 lM). Each point represents the mean values of twelve inde-
pendent experiments. See the text for the corresponding equations and
statistical significance.
FIG. 6. Relationships between CD62P RFI and PRP aggregation (A)
as well as between PAC-1 RFI and PRP aggregation (B), after stimula-
tion with different concentrations of ADP (0.5, 1, 2, 5, 10, 20 lM).
Each point represents the mean values of twelve independent experi-
ments. See the text for the corresponding equations and statistical sig-
nificance.
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tivity), under treatment with aspirine alone, or with aspi-
rin plus clopidogrel respectively, as follows:
y ¼ 2:787x 105:199 ð7Þ
with R2 ¼ 0.996 and P ¼ 0.0022, and
y ¼ 2:012x 39:231 ð8Þ
with R2 ¼ 0.996 and P ¼ 0.0020.
Similarly, significant linear relationships are observed
when comparing PRP maximal aggregation and CD62P
RFI (data not shown).
On the other hand, exponential relationships relate
PRP maximal aggregation and PAC-1 surface expression
(percentage of positivity), under treatment with aspirine
alone, or with aspirin plus clopidogrel respectively, as
follows:
y ¼ e0:535x  3:554  1013 ð9Þ
with P ¼ 0.0012, and
y ¼ e0:285x  3:408  106 ð10Þ
with P ¼ 0.0024.
Similarly, significant exponential relationships are
observed when comparing PRP maximal aggregation and
PAC-1 RFI (data not shown).
The before- and after-procedure mean levels of fibrino-
gen were 285.1 6 24.1 and 314.14 6 18.17 mg/dl,
respectively, while the corresponding mean platelet
counts in the PRP (number of cells per microliter) were
316,419 6 25,865 and 327,019 6 22,166, respectively.
The before- and after-procedure mean values of the
VASP-P PRI (as percentage) were 79.243 6 1.531 and
60.554 6 4.342, respectively.
DISCUSSION
In the present study we applied flow cytometric pro-
tocols and optical aggregometry (type Born) to evalua-
tion of blood from healthy subjects, to establish eventual
mathematical relationships between early events of plate-
let activation and PRP aggregation, after stimulation with
different concentrations of ADP.
Moreover, we extended the evaluation to a group of is-
chemic patients under two different settings of antiplate-
let aggregation, with aspirin alone or with a combination
of aspirin plus clopidogrel, respectively.
Our preliminary results from donors showed the exis-
tence of a linear relationship between the earliest event
of platelet activation, represented by Ca2þ mobilization
from internal stores, and the release reaction of a-gran-
ules, indirectly quantified as surface expression (percent-
age) of the P-selectin molecule (CD62P) [Eq. (1)]. Taking
into account that the granules release reaction is directly
dependent on cytoskeleton rearrangement induced by
Ca2þ mobilization, the Eqs. (2), (3), and (5) seem to
confirm that platelet aggregation relates linearly with
modifications of actin filaments and cytoplasmic Ca2þ
variations upon activation with ADP. The simultaneous
evaluation of PRP aggregation and flow cytometric mea-
surement of platelet filamentous actin (F-actin) content
(18,19) could confirm this hypothesis.
Moreover, platelet PAC-1 surface expression related
with cytoplasmic Ca2þ variations by statistically signifi-
cant polynomial relationships (data not shown), as per-
centage of positivity (P ¼ 0.0008) or RFI (P ¼ 0.0076),
and reached its maximum at concentration of ADP
20 lM, with a saturation-like kinetics. Probably, this aspect
represents the resulting phenomenon of epitopes confor-
mational changes (2), receptor clustering (20), as well as
ADP dose-dependent receptor internalization (21).
Exponential relationships [Eqs. (4) and (6)] were
observed between PRP aggregation and platelet PAC-1
expression, as percentage or RFI.
At present, a combined anti-platelet aggregation ther-
apy with aspirin plus clopidogrel is widely used in coro-
nary ischemic patients to prevent acute thrombosis and
stent restenosis (22–24).
FIG. 7. Linear correlations between the actually measured percen-
tages of aggregation inhibition (ADP 5 lM) and that predicted using
the relationships based on CD62P percentage of positivity (A, R2 ¼
0.627, P ¼ 0.0013) or RFI (B, R2 ¼ 0.577, P ¼ 0.0026).
36 SBRANA ET AL.
Cytometry Part B: Clinical Cytometry DOI 10.1002/cyto.b
In both the clinical settings of our patients, we
observed that the relationships between the expression of
platelet activation markers and PRP aggregation in
response to ADP were similar to that observed in healthy
subjects. This demonstrates the persistence of conserved
patterns of platelet response, and suggests the possibility
to use flow data to predict aggregometric response under
therapies with platelet ADP receptors inhibitory drugs.
We found that the highest percentage of PRP aggrega-
tion inhibition (mean value ¼ 40.193%), after clopidogrel
administration, was obtained with ADP 5 lM.
Therefore, on the basis of the above indicated relation-
ships obtained before and after procedure, we used flow
cytometric data, actually obtained from each patients at
this ADP concentration (5 lM), to verify their capacity
to predict aggregation inhibition.
Significant correlations existed between the percentages
of aggregation inhibition, predicted on the basis of the
CD62P expression relationships (as percentage of positiv-
ity or RFI) obtained before and after procedure, and the
actually measured aggregation inhibitions (Fig. 7).
These correlations were similar to that obtained using
the percentages of CD62P expression inhibition (as per-
centage of positivity or RFI) actually measured for each
patient before and after procedure (Fig. 8).
Linear correlations existed also between the percen-
tages of aggregation inhibition, predicted on the basis of
the CD62P percentage of positivity (P ¼ 0.0031, R2 ¼
0.563) or RFI (P ¼ 0.0018, R2 ¼ 0.602), and the down-
modulation of the VASP-P PRI.
Moreover, linear correlations were observed between
the percentages of CD62P expression inhibition (as per-
centage of positivity) (P ¼ 0.0025, R2 ¼ 0.579) or RFI (P
¼ 0.005, R2 ¼ 0.527), and the VASP-P PRI actually meas-
ured for each patient before and after procedure.
On the contrary, the exponential relationships, since
lowering and expanding the values corresponding
respectively to the lowest and to the highest measure-
ments of the PAC-1 expression range (as percentage, or
RFI), did not show a significant correspondence
between the predicted and the actually measured aggre-
gometric values (data not shown). Also linear and semi-
logarithmic transformations were unable to establish a
significant correspondence (data not shown).
Moreover, the individual flow cytometric PAC-1
expression down modulation (as percentage of positivity
or RFI) was not significantly correlated with the actually
observed aggregation inhibition (data not shown).
On the other hand, the individual flow cytometric
PAC-1 expression down modulation correlated signifi-
FIG. 9. Linear correlations between the actually measured VASP-P
PRI inhibition (%) and the individually measured variations (%) of
PAC-1 percentage of positivity (A, R2 ¼ 0.539, P ¼ 0.0043) or RFI
(B, R2 ¼ 0.635, P ¼ 0.0011).
FIG. 8. Linear correlations between the actually measured percen-
tages of aggregation inhibition (ADP 5 lM) and the individually meas-
ured variations (%) of CD62P percentage of positivity (A, R2 ¼ 0.602,
P ¼ 0.0018) or RFI (B, R2 ¼ 0.614, P ¼ 0.0015).
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cantly with the individual VASP-P PRI inhibition, as per-
centage of positivity or RFI (Fig. 9).
Interestingly, only a weak correspondence (P ¼
0.0699) existed for each patient between the actually
measured aggregation inhibition (ADP 5 lM) and the
before and after procedure down-modulation of the
VASP-P PRI. This observation brings new insights to
the conclusions reported in a recent paper (25), were
a clear correlation between VASP-P assay and light-
transmission aggregometry has been found in in vitro
experiments performed on blood from young healthy
subjects.
If the association of aspirin and clopidogrel is sup-
posed to ameliorate the efficacy of the antiplatelet
aggregation regimens in ischemic patients, our data sug-
gest that the evaluation of platelet cytoskeleton modifi-
cations in response to ADP represents an important
functional aspect to predict the efficacy of treatment. In
particular, the changes of the CD62P molecule expres-
sion, linearly correlated with intra-platelet Ca2þ levels,
seem to be predictive of the aggregometric response to
ADP of patients undergoing therapy with P2Y12 inhibi-
tory drugs.
In fact, the significant relationships observed between
the CD62P-based predicted aggregometric variations and
the down modulation of VASP-P PRI indicates that the
expression of this molecule is able to reflect simultane-
ously the global platelet cytoskeletal modifications in
response to ADP, or the individual clopidogrel-induced
P2Y12 receptor signaling inhibition.
These preliminary data relating CD62P expression and
PRP aggregation should be extended on a more wide
number of patients, accordingly with our settings of
therapy. Moreover, the used ADP concentrations should
be further subdivided in more closed intervals, to deter-
mine accurate and always valid relationships during ther-
apy with aspirin alone or with aspirin plus clopidogrel.
Finally, it should be interesting to evaluate if the above
described relationships can be improved using imped-
ance-based whole blood platelet aggregation methods
that, as reported in the literature, offer a higher sensitiv-
ity for anti-platelet drug effects than optical aggregome-
try (26,27).
On the contrary, the complex relationships between
PAC-1 expression and intra-platelet Ca2þ modifications
as well as between PAC-1 expression and platelet
aggregation make the modulation of this marker inef-
fective in predicting the aggregation response to ADP.
The significant correspondence found between the
individual PAC-1 expression inhibition and VASP-P PRI
down-modulation suggest that this activation marker
can be used only to monitor the level of inhibition of
the P2Y12 receptor intraplatelet signaling induced by
clopidogrel.
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